{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:30:19Z","timestamp":1786649419465,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A new peptide analgesic, a highly selective \u03bc1-opioid receptor agonist (Taphalgin\u00ae) has shown the high efficacy in treating acute postoperative and chronic oncological pain, it appears to be a promising option for the treatment of patients with severe pain in outpatient clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Prospective observational study with a control period 4 hours after a single injection. The onset and peak of the analgesic effect, duration of effect, patient satisfaction and tolerability of therapy were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 37 patients participated in the study. The pain intensity before the injection was 8.9 \u00b1 1.2 according to numeric rating scale. Causes of severe pain included: radicular, oncologic and lumbar pain, vertebral fractures, joint injuries, tendon ruptures and others (e.g., hip fracture, nerve injury). Up to 95% of patients were already receiving pain therapy from non-steroidal anti-inflammatory drugs to strong opioids. After injection, pain intensity decreased with a peak at 30-45 minutes from 8.9\u00b11.2 to 3.2\u00b12.8 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.0001) points on numeric rating scale and lasted for more than 3 hours. There was no difference in pain intensity at rest and with movement. Adverse events were reported in 19 of 37 patients (51.3%). Most adverse events were non-serious, did not require treatment and resolved on their own.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The \u03bc1-opioid receptor agonist Taphalgin\u00ae demonstrates high efficacy, ease of use, rapid onset of effect and good tolerability in patients with severe pain syndrome in outpatient settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sja.sja_486_25","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:00:53Z","timestamp":1767337253000},"page":"23-26","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of \u03bc1-opioid receptor agonist (Taphalgin\u00ae) for emergency analgesia in outpatient practice"],"prefix":"10.4103","volume":"20","author":[{"given":"Alexey G.","family":"Voloshin","sequence":"first","affiliation":[{"name":"Pain Management Institute, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kseniya N.","family":"Avetisova","sequence":"additional","affiliation":[{"name":"Pain Management Institute, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natal\u2019ya V.","family":"Smirnova","sequence":"additional","affiliation":[{"name":"Pain Management Institute, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"65","DOI":"10.14412\/2074-2711-2010-120","article-title":"Management of patients with back pain in outpatient practice","volume":"4","author":"Gerasimova","year":"2010","journal-title":"Neurol Neuropsychiatry Psychosom"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14412\/1995-4484-2007-832","article-title":"Frequency and nature of lower back pain among outpatient patients in Moscow. Report I","volume":"45","author":"Erdes","year":"2007","journal-title":"Sci Pract Rheumatol"},{"issue":"1S","key":"R3-20260421","first-page":"4","article-title":"Overview of Pain Management","volume":"4","author":"Schim","year":"2004","journal-title":"Pain Practice"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"38","DOI":"10.17116\/onkolog20221105138","article-title":"The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial","volume":"11","author":"Abuzarova","year":"2022","journal-title":"P A Herzen J Oncol"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"36","DOI":"10.17650\/2222-1468-2024-14-2-36-47","article-title":"Selective opioid agonist Taphalgin as a component of postoperative analgesia in various surgical areas: \u201cNIKITA\u201d observational multicenter study","volume":"14","author":"Karelov","year":"2024","journal-title":"Head Neck Tumors (HNT)"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fncel.2013.00245","article-title":"Desensitization properties of P2X3 receptors shaping pain signaling","volume":"7","author":"Giniatullin","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0306-4522(01)00342-6","article-title":"Depletion of substance P from rat primary sensory neurons by ATP, an implication of P2X receptor-mediated release of substance P","volume":"7","author":"Nakatsuka","year":"2001","journal-title":"Neuroscience"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1476-5381.2010.00796.x","article-title":"AF-353, a novel, potent and orally bioavailable P2X3\/P2X2\/3 receptor antagonist","volume":"160","author":"Gever","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3897\/rrpharmacology.5.38520","article-title":"Maximum tolerant dose and analgesic activity of PT1 peptide","volume":"5","author":"Palikova","year":"2019","journal-title":"Res Results Pharmacol"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev.neuro.24.1.487","article-title":"The vanilloid receptor: A molecular gateway to the pain pathway","volume":"24","author":"Caterina","year":"2001","journal-title":"Annu Rev Neurosci"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1134\/S160767290901013X","article-title":"Analgesic effect of a polypeptide inhibitor of the TRPV1 receptor in noxious heat pain models","volume":"424","author":"Andreev","year":"2009","journal-title":"Dokl Biochem Biophys"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/nedt.2007.3.1.69","article-title":"Ziconotide: A review of its pharmacology and use in the treatment of pain","volume":"3","author":"McGivern","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17650\/2222-1468-2022-12-2-89-107","article-title":"Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: Review of the results of phase I and II clinical trials","volume":"12","author":"Kosorukov","year":"2022","journal-title":"Head Neck Tumors (HNT)"},{"key":"R14-20260421","doi-asserted-by":"crossref","first-page":"150","DOI":"10.21320\/1818-474X-2024-2-150-158","article-title":"Pain intensity profile after a single injection of the peptide analgesic Taphalgin\u00ae in traumatology and orthopedic patients: Prospective observational cohort study","volume":"2","author":"Karelov","year":"2024","journal-title":"Ann Crit Care"},{"key":"R15-20260421","doi-asserted-by":"crossref","first-page":"38","DOI":"10.21320\/1818-474X-2024-3-38-47","article-title":"Efficacy of tyrosyl-D-arginyl-phenylalanyl-glycin amide for postoperative anesthesia in laparoscopic gynecology: A randomized controlled trial","volume":"3","author":"Dmitriev","year":"2024","journal-title":"Ann Crit Care"},{"key":"R16-20260421","doi-asserted-by":"crossref","first-page":"78","DOI":"10.17650\/2782-3202-2024-4-1-78-84","article-title":"New peptide analgesic, \u03bc1-opioid receptor agonist tafalgin, in multimodal pain management. First results of using in a multidisciplinary hospital","volume":"4","author":"Gruzdev","year":"2024","journal-title":"MD-Onco"}],"container-title":["Saudi Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sja.sja_486_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:53:58Z","timestamp":1786647238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sja.sja_486_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sja.sja_486_25","relation":{},"ISSN":["1658-354X","0975-3125"],"issn-type":[{"value":"1658-354X","type":"print"},{"value":"0975-3125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}